2.53
6.30%
-0.17
Adagene Inc ADR stock is currently priced at $2.53, with a 24-hour trading volume of 11,375.
It has seen a -6.30% decreased in the last 24 hours and a -11.07% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.67 pivot point. If it approaches the $2.51 support level, significant changes may occur.
Adagene Inc ADR Stock (ADAG) Financials Data
Adagene Inc ADR (ADAG) Revenue 2024
ADAG reported a revenue (TTM) of $18.11 million for the quarter ending December 31, 2023, a +77.99% rise year-over-year.
Adagene Inc ADR (ADAG) Net Income 2024
ADAG net income (TTM) was -$18.95 million for the quarter ending December 31, 2023, a +74.11% increase year-over-year.
Adagene Inc ADR (ADAG) Earnings per Share 2024
ADAG earnings per share (TTM) was -$0.4375 for the quarter ending December 31, 2023, a +76.03% growth year-over-year.
Adagene Inc ADR Stock (ADAG) Latest News
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
GlobeNewswire Inc.
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
GlobeNewswire Inc.
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket
Benzinga
About Adagene Inc ADR
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Cap:
|
Volume (24h):